Achieve Life Sciences (NASDAQ:ACHV) Shares Up 7.8% – Should You Buy?

Posted by George Bondi on Jul 1st, 2026

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Free Report) traded up 7.8% during mid-day trading on Wednesday . The company traded as high as $7.02 and last traded at $7.04. 524,709 shares traded hands during trading, a decline of 59% from the average daily volume of 1,276,113 shares. The stock had previously closed at $6.53.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ACHV shares. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Achieve Life Sciences in a research note on Monday, June 22nd. Wall Street Zen upgraded Achieve Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, May 17th. Canaccord Genuity Group set a $13.00 target price on Achieve Life Sciences and gave the stock a “buy” rating in a research report on Monday, April 20th. Raymond James Financial began coverage on Achieve Life Sciences in a report on Friday, June 26th. They set a “strong-buy” rating and a $20.00 price target on the stock. Finally, Weiss Ratings raised Achieve Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $16.00.

View Our Latest Stock Report on ACHV

Achieve Life Sciences Stock Up 4.1%

The business’s 50 day simple moving average is $5.06 and its 200-day simple moving average is $4.60. The company has a market cap of $697.57 million, a price-to-earnings ratio of -6.07 and a beta of 2.27. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.62 and a current ratio of 2.62.

Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.11. Sell-side analysts expect that Achieve Life Sciences, Inc. will post -0.81 earnings per share for the current year.

Institutional Investors Weigh In On Achieve Life Sciences

Several large investors have recently made changes to their positions in the company. AQR Capital Management LLC bought a new position in Achieve Life Sciences during the first quarter valued at approximately $32,000. Magnolia Capital Advisors LLC bought a new stake in Achieve Life Sciences in the fourth quarter worth approximately $64,000. Jefferies Financial Group Inc. bought a new stake in Achieve Life Sciences in the fourth quarter worth approximately $84,000. HRT Financial LP acquired a new position in shares of Achieve Life Sciences during the 4th quarter worth $93,000. Finally, OneDigital Investment Advisors LLC acquired a new position in shares of Achieve Life Sciences during the 3rd quarter worth $63,000. Institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Company Profile

(Get Free Report)

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.